Could in-hospital use of continuous glucose monitors become a new normal after the COVID-19 pandemic? Dexcom CEO Kevin Sayer thinks so.
As the pandemic ramped up in March, FDA issued temporary guidance allowing increased remote monitoring of hospital patients in order to limit contact with hospital staff. The guidance included CGMs made by companies such as Dexcom (NSDQ:DXCM) and Abbott (NYSE:ABT).
Preliminary data suggest that CGMs helped, according to Sayer, who spoke with MassDevice today as part of a virtual version of the American Diabetes Association’s annual Scientific Sessions. (Hear some clips during our DeviceTalks Weekly podcast at the end of the week.)
“We’ve even heard stories of patients who came in and they were about to ventilate them, and then they realized maybe their glucose values were out of control. Getting their glucose values unde…